ASX 100 News & Analysis

This healthcare company still has plenty of growth potential, but it’s been a rocky road for investors recently.

Santos’ disappointing returns over the past twenty years are mostly a result of bad timing. The timing of its potential departure from the ASX could...

99% of investors won’t be the next Warren Buffett – luckily, we don’t need that to be successful.

Unless regulators step in, the ASX looks set to lose another icon.

We think Virgin’s offer price reflects benign industry conditions that are unlikely to remain so good forever.

Discover our top pick for international exposure.

WiseTech’s competitive position is incredibly strong and looks set to underpin formidable sales growth for the foreseeable future.

Investors savaged Nufarm stock as oversupply of fish oil hit prices in a key product line. We think the reaction is overdone.

Our analyst’s best picks from the Aussie tech sector.

See how the two popular options compare.